Valuation: Protagonist Therapeutics, Inc.

Market Cap 9.38B 8.18B 7.7B 7.02B 13.15B 899B 13.17B 92.26B 35.56B 458B 35.24B 34.46B 1,477B P/E 2026 *
31.2x
P/E 2027 * -306x
Enterprise Value 8.84B 7.71B 7.26B 6.61B 12.4B 847B 12.41B 86.97B 33.52B 432B 33.22B 32.48B 1,393B EV / Sales 2026 *
16.3x
EV / Sales 2027 * 43.6x
Free-Float
97.68%
Yield 2026 *
-
Yield 2027 * -
1 day+1.38%
1 week-1.89%
Current month-1.87%
1 month-6.05%
3 months+28.46%
6 months+46.64%
Current year+65.99%
1 week 140.44
Extreme 140.435
146.5
1 month 140.44
Extreme 140.435
158.08
Current year 77
Extreme 77
160.81
1 year 62.24
Extreme 62.24
160.81
3 years 13.72
Extreme 13.72
160.81
5 years 6.91
Extreme 6.91
160.81
10 years 4.47
Extreme 4.47
160.81
Manager TitleAgeSince
Chief Executive Officer 69 30/11/2008
Director of Finance/CFO 52 17/04/2022
Chief Tech/Sci/R&D Officer - 31/03/2026
Director TitleAgeSince
Director/Board Member 69 30/11/2008
Chairman 71 18/03/2014
Director/Board Member 69 30/06/2016
Date Insider Type Main position Quantity % Market Cap. Importance
10/09/26 Exercice

Chief Executive Officer

21,834 0.0337%
03/09/26 Don

Chief Executive Officer

-510 0.0008%
11/08/26 Exercice

Chief Executive Officer

102,717 0.1597%
Change 5-day change 1-year change 3-year change Capi.($)
+1.38%-1.89%+133.09%+753.83% 9.38B
+0.59%+2.73%+1.03%+28.74% 46.68B
+1.30%+1.58%+44.15%+35.50% 44.42B
+0.95%-6.02%+342.72%+532.41% 41.32B
+4.23%+3.35%+9.35%+94.73% 41.58B
+1.11%+1.45%+11.52%+45.96% 30.14B
+1.94%+4.84%+25.19%+159.21% 17.42B
+0.37%-10.32% - - 15.6B
+2.12%+8.18%+24.78%+41.21% 15.54B
+0.24%+25.43%-11.57% - 14.08B
Average +1.41%+2.72%+64.47%+211.45% 27.62B
Weighted average by Cap. +1.52%+1.58%+72.21%+165.23%

Financials

2026 *2027 *
Net sales 542M 473M 445M 406M 760M 51.95B 761M 5.33B 2.06B 26.46B 2.04B 1.99B 85.4B 203M 177M 167M 152M 285M 19.49B 286M 2B 771M 9.93B 764M 747M 32.03B
Net income 324M 282M 266M 242M 454M 31.02B 455M 3.18B 1.23B 15.8B 1.22B 1.19B 50.99B -32.12M -28.01M -26.38M -24.02M -45.04M -3.08B -45.1M -316M -122M -1.57B -121M -118M -5.06B
Net Debt -538M -469M -442M -403M -755M -51.57B -756M -5.29B -2.04B -26.27B -2.02B -1.98B -84.76B -511M -446M -420M -382M -717M -48.96B -718M -5.03B -1.94B -24.94B -1.92B -1.88B -80.49B
Logo Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV).
Employees
141
Date Price Change Volume
21/09/26 US$144.98 +1.38% 822,198
18/09/26 US$143.00 -0.49% 1,837,204
17/09/26 US$143.70 +0.60% 558,901
16/09/26 US$142.84 -0.39% 507,311
15/09/26 US$143.40 -2.96% 637,522
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
144.98USD
Average target price
174.69USD
Spread / Average Target
+20.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTGX Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!